Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Why the study?
Triglyceride-rich lipoproteins and their remnants causally increase cardiovascular risk and contribute to residual risk in patients on optimized LDL-lowering therapy, necessitating an updated consensus on their biology and therapeutic targeting.
Design
Consensus statement
Authors
Discussion
Loading...
Member takes
Implication
Supports residual risk assessment in ASCVD; leaves open dedicated trials of emerging triglyceride-targeted therapies.
Key Points
Key points are not available for this paper at this time.
Cite This Study
Ginsberg et al. (2021) studied this question.